| Identification | Back Directory | [Name]
4-[5-(4-chlorophenyl)-2-phenyl-3,4-dihydropyrazol-3-yl]-N,N-dimethylaniline | [CAS]
128519-30-2 | [Synonyms]
4-[5-(4-chlorophenyl)-2-phenyl-3,4-dihydropyrazol-3-yl]-N,N-dimethylaniline
Benzenamine, 4-[3-(4-chlorophenyl)-4,5-dihydro-1-phenyl-1H-pyrazol-5-yl]-N,N-dimethyl- | [Molecular Formula]
C23H22ClN3 | [MOL File]
128519-30-2.mol | [Molecular Weight]
375.89 |
| Chemical Properties | Back Directory | [Melting point ]
167-169 °C(Solv: ethanol (64-17-5)) | [Boiling point ]
525.1±60.0 °C(Predicted) | [density ]
1.16±0.1 g/cm3(Predicted) | [pka]
5.09±0.24(Predicted) |
| Hazard Information | Back Directory | [Uses]
Anticancer agent 231 (Compound P5) is a tyrosine protein kinase inhibitor with a IC50 value of 3.95 μM. Anticancer agent 231 inhibits the cell viability, cell proliferation, cell migration and cancer dryness of triple negative breast cancer (TNBC) cells by targeting EGFR-ERK 1/2 signaling pathway, and is expected to play an important role in the field of TNBC disease therapy[1]. | [IC 50]
ERK1; ERK2 | [References]
[1] Satriyo PB, et al. N-phenyl pyrazoline derivative inhibits cell aggressiveness and enhances paclitaxel sensitivity of triple negative breast cancer cells. Sci Rep. 2024 Jun 8;14(1):13200. DOI:10.1038/s41598-024-63778-2 |
|
| Company Name: |
PHARMEKS Ltd.
|
| Tel: |
+7 (495) 702-9648 |
| Website: |
www.pharmeks.com |
|